v3.26.3
Investments, at Fair Value
9 Months Ended
Sep. 30, 2026
Investments, at Fair Value [Abstract]  
INVESTMENTS, AT FAIR VALUE

NOTE 4 - INVESTMENTS, AT FAIR VALUE:

 

  a. Investment in Scilex

 

Background

 

The Company holds the following instruments issued by Scilex, acquired in the 2023 Scilex Transaction and the 2024 Refinancing. For a full description of the terms of these instruments, see Note 4 to the Company’s consolidated financial statements included in the 2025 Form 10-K.

 

  a. Tranche A Note – a senior secured promissory note (original principal amount of $101,875), guaranteed by Scilex’s domestic subsidiaries and secured by a first-priority security interest in substantially all of Scilex’s assets. As of September 30, 2026, the outstanding principal balance was $7,675, accrued interest was $19,608 and the exit fee was $3,056.

 

  b. Tranche B Note – the Company’s $25,000 share of senior secured convertible notes, repayable quarterly and maturing on October 8, 2026. As of September 30, 2026, following principal repayments of $17,007 and interest payments of $2,609, the outstanding principal balance was $7,993 and accrued interest was $20.
     
  c. Tranche B Warrants – warrants to purchase an aggregate of 207,143 shares of Scilex common stock at exercise prices ranging from $20.00 to $36.40 per share, of which warrants to purchase 100,000 shares were issued on February 19, 2026 in consideration for the deferral of an October 2025 amortization payment.

 

  d. Royalty Purchase Agreement – the right to receive 4% of worldwide net sales of ZTLido, SP-103 and related products for a period of ten years.

 

All Scilex securities held by the Company are subject to a beneficial ownership limitation that restricts the Company’s holdings to a maximum of 9.99% of Scilex’s outstanding shares at any time.

 

Developments during the nine months ended September 30, 2026

 

During the period, the maturity of Scilex’s outstanding obligations under the Tranche A Note and the Tranche B Note was extended several times, in consideration of which Scilex agreed to pay the Company an extension fee of $1,000, which was received by the Company.

 

Subsequent to September 30, 2026, the date for payment in full of the outstanding obligations under the Tranche A Note and the Tranche B Note was extended to November 9, 2026. See Note 19a.

 

Accounting treatment and fair value measurement

 

The table below presents the fair value breakdown as of September 30, 2026:

 

    Tranche A Note     Tranche B Note     Total  
    Amount     Accrued
Interest
    Fair
Value
    Amount     Accrued
Interest
    Fair
Value
    Fair
Value
 
Notes   $ 7,675     $ 19,608     $ 18,716     $ 7,993     $ 20     $ 4,591     $ 23,307  
Warrants     -       -       -       207       -     $ 97     $ 97  
Royalty Purchase Agreement payment     -       -       -       -       -     $ 1,749     $ 1,749  
September 30, 2026                   $ 18,716               -     $ 6,437     $ 25,153  

 

Tranche A Note

 

The Company elected the fair value option for the Tranche A Note and changes in value are recorded under financial income, net.

 

The discount rate of the Tranche A Note was based on the B- rating zero curve in addition to a risk premium which takes into account the credit risk of Scilex and ranged from 132.08 % to 132.31%.

 

Tranche B Note, Warrants and Royalty Purchase Agreement

 

The Company elected the fair value option for the Tranche B Note and the Royalty Purchase Agreement, the Tranche B Warrants meet the definition of a derivative and therefore will be measured at fair value. Changes in value are recorded under financial income, net and include interest income on the Tranche B Note.

 

The valuation of the Tranche B Note was performed based on the discounted value of the Tranche B Note’s liability component, using a probability-weighted average of scenarios for the expected repayment date and discount rates ranging from 131.55% to 132.31%.

 

The fair value of the Tranche B Warrants was calculated based on Black and Scholes model.

 

The following table summarizes the assumptions and estimates used to value the Warrants as of September 30, 2026:

 

Parameters and Assumptions   Warrants  
Share Price   $ 4.45  
Conversion Rate     -  
Floor Rate     -  
Expected Term     3.02 – 3.21  
Volatility     69.04 – 69.54 %
Risk Free Rate     4.933 – 4.944 %
Yield     -  
Exercise Price   $ 20 – 36.40  
Dividend Rate     0 %

 

The value of the Royalty Purchase Agreement was calculated according to the royalty payment schedule and the aggregation of discounted cash flows derived from the royalty payments, using a discount rate ranging from 131.03% to 134.16%.

 

As of September 30, 2026, and December 31, 2025, the fair value of the Tranche B Note was less than the aggregate unpaid principal balance (which includes interest payable on maturity) by $3,422 and $4,488, respectively.

 

The table below represents the fair value composition of the Tranche B Note:

 

    September 30, 2026     December 31, 2025  
    Short term     Long term     Total     Short term     Long term     Total  
Tranche B Note   $ 4,591     $ -     $ 4,591     $ 11,473     $ -     $ 11,473  
Warrant   $ -     $ 97     $ 97     $ -     $ 850     $ 850  
Royalty Purchase Agreement   $ 944     $ 805     $ 1,749     $ 1,072     $ 1,137     $ 2,209  
Total   $ 5,535     $ 902     $ 6,437     $ 12,545     $ 1,987     $ 14,532  

 

Scilex Transaction Summary

 

The table below represents the fair value cycle of 2023 Scilex Transaction and 2024 Refinancing throughout December 31, 2025 and September 30, 2026:

 

    Tranche A     Tranche B     Total  
Balance as of December 31, 2024   $ 16,486     $ 18,322     $ 34,808  
Amounts receivable from the royalty agreement (*)     -       (1,640 )     (1,640 )
Principal payments     -       (9,875 )     (9,875 )
Proceeds from the sale of Subsequent Penny Warrants     (28,500 )     -       (28,500 )
Interest payments     -       (1,845 )     (1,845 )
Change in fair value     35,077       9,570       44,647  
Balance as of December 31, 2025     23,063       14,532       37,595  
Amounts receivable from the royalty agreement (*)     -       (1,118 )     (1,118 )
Principal payments     -       (7,132 )     (7,132 )
Interest payments     -       (764 )     (764 )
Change in fair value (**)     (4,347 )     919       (3,428 )
Balance as of September 30, 2026   $ 18,716     $ 6,437     $ 25,153  

 

(*) As of September 30, 2026 and December 31, 2025, $773 and $449, respectively, were included under prepaid expenses and other current assets.

 

(**) During the nine months ended September 30, 2026, the Company received an extension fee of $1,000 from Scilex in consideration for the extension of the maturity of the Tranche A Note and the Tranche B Note. The extension fee is presented separately within “Financial income, net” (see Note 15) and is not included in the change in fair value above. See “Developments during the nine months ended September 30, 2026” above.

 

Financial income recognized in respect of the 2023 Scilex Transaction and the 2024 Refinancing for the nine and three months ended September 30, 2026 and 2025 was a loss of $3,428 and $5,895, and income of $38,457 and $34,163, respectively.

 

b. Profit Sharing Loan Agreement

 

On September 4, 2024, the Company entered into a loan agreement (the “Profit Sharing Loan Agreement”) with Rabi Binyamin 4 Tama 38 Ltd. (the “Borrower”) to finance a real estate project (the “Project”). According to the terms of the Profit Sharing Loan Agreement, Oramed agreed to loan NIS 5,500 thousands ($1,523) (the “Loan Principal”) to the Borrower. NIS 4,700 thousands ($1,307) was loaned upon signing the Profit Sharing Loan Agreement and an additional NIS 800 thousands ($237) will be loaned upon achievement of certain milestones (“Additional Payment”). On October 28, 2025, the Borrower met the milestones and became entitled to the Additional Payment. The Additional Payment was funded by the Company on June 10, 2026.

 

Upon completion of the Project, the Company is entitled to receive the Loan Principal and the greater of: (i) 20% annual interest of the Loan Principal and (ii) 40% of the Project profits.

 

On July 1, 2026, the Company amended the Profit Sharing Loan Agreement to increase the total loan amount to NIS 8,986 thousands ($3,016), including amounts previously advanced to the Borrower. On July 2, 2026, the Company funded an additional NIS 3,042 thousands ($1,013). In addition, the Company’s entitlement upon completion of the Project was amended to the greater of: (i) 20% annual interest on the outstanding loan principal or (ii) 60% of the project profits.

 

On September 9, 2026, the Company provided a bank guarantee in the amount of NIS 2,000 thousands ($663), valid until March 1, 2027. As security for the guarantee, the bank placed a lien on the Company’s entire U.S. dollar bank deposit in the amount of $868, which is presented as a restricted deposit within prepaid expenses and other current assets.

 

The Company decided to designate the Profit Sharing Loan Agreement as a whole under the Fair-Value option in accordance with Accounting Standards Codification (“ASC”) Topic 825 “Financial Instruments”. The valuation of the Profit Sharing Loan Agreement was based on various project profit scenarios. The Company used the Wang Transform model, a risk-neutral probabilities method, with an expected term of 2.51 years, a curve rate of 16.61% and a risk spread of 0.43%.

 

As of September 30, 2026 and December 31, 2025, the fair value of the Profit Sharing Loan Agreement, including the additional amounts advanced thereunder, was $3,338 and $1,890, respectively.

 

Financial income (loss) recognized in respect of the Profit Sharing Loan Agreement was income of $193 and $196 for the nine and three months ended September 30, 2026, respectively. In the corresponding 2025 periods, the Company recognized income of $161 and $64, respectively.

 

c. Ruby Sapphire II

 

On December 29, 2025, the Company entered into an agreement and committed to invest NIS 7,000 thousands ($2,185) as a limited partner in Ruby Capital Investment Fund Sapphire II, Limited Partnership (“Ruby Sapphire II”), an Israeli private investment fund. The Company’s commitment may be drawn down over time in accordance with the fund’s partnership agreement, and the investment is subject to the risks inherent in private investment funds, including illiquidity and the potential loss of invested capital. On February 5, 2026, the Company funded NIS 1,556 thousands ($499) under this commitment. As of September 30, 2026, no additional amounts had been funded.

 

The Company has elected the fair value option, in accordance with ASC Topic 825, Financial Instruments, to measure its investment in Ruby Sapphire II. The fair value is determined based on the Company’s pro-rata share of the fund’s net asset value as reported by the fund on a quarterly basis (with a one-quarter lag). As of September 30, 2026, the fair value of the investment in Ruby Sapphire II was $449. Financial loss recognized in respect of the Ruby Sapphire II for the nine and three months ended September 30, 2026 was $50 and $15, respectively.

 

d. Junior Participation Interest in 83 Wythe Loan

 

On April 15, 2026, the Company invested $2,500 in a junior participation interest in a senior secured construction loan to 83 Wythe LLC, pursuant to a Junior Participation Agreement with 83 Wythe Senior Investors, L.P (“83 Wythe Loan”). The Company is entitled to a 9% preferred annual return on its invested capital. The loan matures on October 15, 2028, with extension options through October 15, 2029.

 

The Company has elected the fair value option, in accordance with ASC Topic 825, Financial Instruments, to measure its investment in 83 Wythe Loan. The fair value of the investment is determined using a discounted cash flow methodology, based on estimated contractual cash flows and a market-based discount rate. As of September 30, 2026, the fair value of the investment in the 83 Wythe Loan was $2,341. Financial loss recognized in respect of the 83 Wythe Loan for the nine months and three months ended September 30, 2026 was $159 and $41, respectively.

 

  e.

Participation Interest — Warren at Bay Loan

 

On May 13, 2026, the Company invested $3,000 in a participation interest in a senior secured mortgage loan to Warren at Bay LLC, pursuant to a Participation Agreement with A&P Senior Investors, L.P (“Warren at Bay Loan”). The Company is entitled to (i) an 8% per annum interest coupon, payable quarterly in arrears from a dedicated reserve account, and (ii) an additional 4% per annum interest promote, which accrues and compounds annually and is payable in kind upon repayment in full of the loan. The loan matures on May 13, 2029, with extension options through May 13, 2031.

 

The Company has elected the fair value option, in accordance with ASC Topic 825, Financial Instruments, to measure its investment in Warren at Bay Loan. The fair value of the investment is determined using a discounted cash flow methodology, based on estimated contractual cash flows and a market-based discount rate. As of September 30, 2026, the fair value of the investment in the Warren at Bay Loan was $2,703. Financial loss recognized in respect of the Warren at Bay Loan for the nine months and three months ended September 30, 2026 was $265 and $23, respectively. During the nine months ended September 30, 2026, the Company received interest payments of $32 in respect of the Warren at Bay Loan.